Stocksigma LogoStocksigma Logo

Beta Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR)

■ Revenue: 1,37,48,87,594 (+33.0% YoY | +9.5% QoQ) ■ EBITDA: 30,28,04,262 (+42.1% YoY | +10.6% QoQ) ■ EBITDA Margin (%): 22.0 (+141 bps YoY | +23 bps QoQ)

Beta Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR)

Beta Drugs Ltd · Financial Result · 22 Oct 2026, 4:43 pm

Beta Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR) ■ Revenue: 1,37,48,87,594 (+33.0% YoY | +9.5% QoQ) ■ EBITDA: 30,28,04,262 (+42.1% YoY | +10.6% QoQ) ■ EBITDA Margin (%): 22.0 (+141 bps YoY | +23 bps QoQ) ■ PAT: 18,55,07,075 (+51.8% YoY | +17.4% QoQ) ■ EPS (INR): 16.6 (+37.1% YoY | +12.2% QoQ)

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements